Purpose: Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT); however. the toxicity of this pairing is unknown. We report preliminary results on the use of this combination. https://www.diegojavierfares.com/flash-find-Bushranger-Awning-2-5m-W-x-2-0m-L-2-Year-No-Fuss-Warranty-AW2000-best-save/